References
Gebhart BC, Barker BC, Markewitz BA (2007) Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin. Pharmacotherapy 27:476–479
Hoyo I, Martínez-Pastor J, Garcia-Ramiro S, Climent C, Brunet M, Cuesta M et al (2012) Decreased serum linezolid concentrations in two patients receiving linezolid and rifampicin due to bone infections. Scand J Infect Dis 44:548–50
Soriano A, Ortega M, García S, Peñarroja G, Bové A, Marcos M et al (2007) Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid. Antimicrob Agents Chemother 51:2559–63
Gandelman K, Zhu T, Fahmi OA, Glue P, Lian K, Obach RS et al (2011) Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 51:229–36
Egle H, Trittler R, Kümmerer K, Lemmen SW (2005) Linezolid and rifampin: drug interaction contrary to expectations? Clin Pharmacol Ther 77:451–3
Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S et al (2011) Rifampin’s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design. Clin Pharmacol Ther 89:234–42
Horn JR, Hansten, PD (2011). Time course for enzyme induction and deinduction. http://www.pharmacytimes.com/publications/issue/2011/April2011/DrugInteractions-0411
Pea F, Viale P, Cojutti P, Del Pin B, Zamparini E, Furlanut M (2012) Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 67:2034–42
Cattaneo D, Orlando G, Cozzi V, Cordier L, Baldelli S, Merli S et al (2013) Linezolid plasma concentrations and occurrence of drug-related haematological toxicity in patients with gram-positive infections. Int J Antimicrob Agents 41:586–9
Dong HY, Xie J, Chen LH, Wang TT, Zhao YR, Dong YL (2014) Therapeutic drug monitoring and receiver operating characteristic curve prediction may reduce the development of linezolid-associated thrombocytopenia in critically ill patients. Eur J Clin Microbiol Infect Dis 33:1029–35
Transparency declarations
None to declare.
Conflict of interest
All the authors declare no conflict of interest.
Funding
This study was carried out as part of our routine work.
Compliance with ethical standards
This is a retrospective observation describing a case; the patient provided written consent for the case report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gervasoni, C., Simonetti, F.R., Resnati, C. et al. Prolonged inductive effect of rifampicin on linezolid exposure. Eur J Clin Pharmacol 71, 643–644 (2015). https://doi.org/10.1007/s00228-015-1833-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-015-1833-z